Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
553.50    1.00 (0.18%)
Bid:
553.00
Ask:
553.50
Spread: 0.50 (0.09%)
Market Cap: £2.45b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Director/PDMR Shareholding

8 Jul 2014 10:01

Tate & Lyle PLC

Director/PDMR Shareholding

Tate & Lyle PLC (the “Company”) was informed yesterday that on 7 July 2014 a grant of options and awards over the Company’s ordinary shares of 25 pence each in the capital of the Company (“Shares”) was made under the Tate & Lyle 2012 Performance Share Plan (“PSP”) to an Executive Director and the Persons Discharging Managerial Responsibilities (“PDMR”) as detailed in the table below:

Name Role No. of Shares subject to option No of Shares subject to award
Javed Ahmed Executive Director 305,584 -
Robert Gibber PDMR 160,717 -
Rob Luijten PDMR 112,400 -
Olivier Rigaud PDMR 137,746 -
Gabrielle Parisse PDMR - 123,404
Matt Wineinger PDMR - 154,073

Options and awards granted under the PSP will only vest to the extent that certain performance criteria are satisfied by the Company over a three-year performance period which runs from 1 April 2014 to 31 March 2017. No consideration is payable for the grant or exercise of the options or awards.

This notification is made in accordance with DTR 3.1.4R(1)(a) of the Disclosure and Transparency Rules.

Lucie GilbertCompany Secretary8 July 2014

Copyright Business Wire 2014

Date   Source Headline
26th Jul 20245:33 pmRNSTransaction in Own Shares
25th Jul 20245:28 pmRNSTransaction in Own Shares
25th Jul 20242:00 pmRNSResult of AGM
25th Jul 20247:00 amRNSTrading Statement
24th Jul 20245:24 pmRNSTransaction in Own Shares
24th Jul 20245:15 pmRNSTotal Voting Rights
23rd Jul 20245:40 pmRNSTransaction in Own Shares
22nd Jul 20245:26 pmRNSTransaction in Own Shares
19th Jul 20245:33 pmRNSTransaction in Own Shares
18th Jul 20245:37 pmRNSTransaction in Own Shares
18th Jul 202410:00 amRNSDirector/PDMR Shareholding
17th Jul 20245:45 pmRNSTransaction in Own Shares
16th Jul 20245:25 pmRNSTransaction in Own Shares
15th Jul 20245:20 pmRNSTransaction in Own Shares
15th Jul 202411:00 amRNSHolding(s) in Company
12th Jul 20245:55 pmRNSTransaction in Own Shares
12th Jul 202411:00 amRNSBlock listing Interim Review
11th Jul 20245:30 pmRNSTransaction in Own Shares
10th Jul 20245:41 pmRNSTransaction in Own Shares
9th Jul 20245:24 pmRNSTransaction in Own Shares
8th Jul 20245:41 pmRNSTransaction in Own Shares
5th Jul 20245:49 pmRNSTransaction in Own Shares
5th Jul 20242:00 pmRNSDirector/PDMR Shareholding
4th Jul 20245:40 pmRNSTransaction in Own Shares
3rd Jul 20245:29 pmRNSTransaction in Own Shares
2nd Jul 20245:32 pmRNSTransaction in Own Shares
2nd Jul 202411:30 amRNSHolding(s) in Company
1st Jul 20245:29 pmRNSTransaction in Own Shares
1st Jul 202412:30 pmRNSTotal Voting Rights
28th Jun 20245:59 pmRNSTransaction in Own Shares
27th Jun 20245:37 pmRNSTransaction in Own Shares
27th Jun 20244:30 pmRNSCompletes sale of remaining interest in Primient
27th Jun 20243:30 pmRNSHolding(s) in Company
26th Jun 20245:38 pmRNSTransaction in Own Shares
25th Jun 20245:50 pmRNSTransaction in Own Shares
24th Jun 20245:35 pmRNSTransaction in Own Shares
24th Jun 20243:30 pmRNSHolding(s) in Company
21st Jun 20245:45 pmRNSTransaction in Own Shares
21st Jun 20242:45 pmRNSUpdate to the Notice of AGM 2024
20th Jun 20246:03 pmRNSTransaction in Own Shares
20th Jun 20247:05 amRNSLaunch of Share Buyback
20th Jun 20247:00 amRNSCombination of Tate & Lyle and CP Kelco
4th Jun 20245:22 pmRNSAnnual Financial Report and Notice of AGM
4th Jun 202411:00 amRNSDirector/PDMR Shareholding
3rd Jun 202412:00 pmRNSTotal Voting Rights
30th May 202412:15 pmRNSHolding(s) in Company
23rd May 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSSale of remaining interest in Primient JV to KPS
20th May 20241:00 pmRNSDirectorate Change
17th May 20243:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.